Moleculin Biotech ( (MBRX) ) has shared an announcement.
Moleculin Biotech, Inc. announced that its CEO, Walter Klemp, featured in a Virtual Investor segment to discuss the company’s progress, specifically highlighting a Phase 2 clinical trial that evaluates a STAT3 inhibitor in treating glioblastoma. This trial, conducted in collaboration with Northwestern University and funded by the NIH and BrainUp, underscores Moleculin’s commitment to advancing treatments for hard-to-treat cancers. The company continues to make strides with its lead program, Annamycin, for acute myeloid leukemia and is also developing other promising drug candidates targeting various tumors and viruses.
Find detailed analytics on MBRX stock on TipRanks’ Stock Analysis page.
